Benefit of Spectral Information in Patients Suspected for Lung Cancer

Launched by COPENHAGEN UNIVERSITY HOSPITAL AT HERLEV · May 31, 2024

Keywords

ClinConnect Summary

This clinical trial, called "Benefit of Spectral Information in Patients Suspected for Lung Cancer," is looking at a new type of imaging called photon counting CT (PCCT) to see how it can help doctors better understand and follow up on potential lung cancer cases. The study will compare the traditional CT scans and a special type of scan called PET, which helps show how active cancer might be. By using PCCT, researchers hope to determine if having extra information from these scans can lead to more accurate diagnoses and better patient care.

To participate in this trial, individuals must be referred to Copenhagen University Hospital for suspected lung cancer and provide informed consent. Some patients might not qualify if they have already been diagnosed with lung cancer elsewhere or if they have certain health conditions that prevent them from receiving treatment. Participants will undergo imaging tests and their results will be monitored over a year to see if any additional tests are needed. The study will also look at the costs associated with these scans, aiming to find ways to save money while ensuring patients receive the best care possible.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients suspected of lung cancer refered to Copenhagen University Hospital as per the guidelines from the danish national health authorities from either the general practitioner or from the department of pulmonology.
• • Informed consent
• Exclusion Criteria:
• • Patients who cannot tolerate intravenous iodinated contrast
• • Already verified lung cancer from another institution
• • Comorbidities that exclude the patient from receiving treatment
• • Lack of reference standard in the form of either histology or follow-up
• • Known extrapulmonary malignancy
• • Technical limitations within the scans/reconstructions
• • other

Trial Officials